Frontier

Human Capability

Keeping people and populations healthier, stronger and more adaptable.

Adjacent research horizon
Adjacent research horizonWytham Lane has no dedicated strategy, vehicle or portfolio in this area today. This page describes research interest and the conditions under which that could change.
Fig. · The Living Network · Neural pathways
Why it sits beside our first frontier

Biology has more than one proving ground

Recovery after injury, immune function, tissue preservation and the ability to withstand physiological stress arise in ageing. They also arise in surgery, rehabilitation, infectious disease and elite sport. Some of the biological pathways and measurement tools are shared, even where the products and customers are different.

Sports and performance science offer a highly measured setting. Recovery, sleep, load and physical function can be observed frequently, and an intervention can sometimes be seen to change a measurable response in weeks rather than years. That makes it a useful place to develop measurement tools and test early hypotheses.

Biological resilience spans chronic ageing and acute threats: infection, injury, inflammation, organ protection and recovery. Protecting an organ from acute injury is not the same as reversing chronic degeneration, even where the pathways overlap. A company that serves both has to earn that claim through evidence.

Plate III · Point-light walkers, after Johansson (1973). Movement is one of the most information-rich signals the body gives, and one of the easiest to measure often.
Questions we are studying

Research interests

  • Can we measure recovery reliably and often enough to act on it?
  • Can we protect organs from acute injury and stress?
  • Which resilience mechanisms are shared with ageing, and which are not?
Scope

What this is not

Our interest is in the science, tools and infrastructure of performance and recovery. It does not extend to team ownership, media rights or athlete merchandise, and athlete outcomes are never treated as proof of efficacy in ageing populations.

Before a dedicated strategy

What would need to be true

  • A specialist team with relevant scientific and commercial depth.
  • Evidence that measurement tools translate across populations.
  • Capital structured for the risks and timelines involved.
Other frontiers